Liaoran Wang, Maho Terashita, Kohei Kinoshita, Akihiro Maenaka, Ivy A Rosales, David K C Cooper
{"title":"终末期肾衰竭的未来治疗:基因编辑猪肾异种移植。","authors":"Liaoran Wang, Maho Terashita, Kohei Kinoshita, Akihiro Maenaka, Ivy A Rosales, David K C Cooper","doi":"10.1016/j.xkme.2025.101041","DOIUrl":null,"url":null,"abstract":"<p><p>In patients with end-stage kidney disease, kidney transplantation from a living or deceased human donor offers a much-improved quality and length of life. Gene-edited pigs might provide an alternative source of kidneys for clinical transplantation (xenotransplantation). The major pathobiological barriers to successful pig kidney xenotransplantation have steadily been overcome by the following methods: (1) genetic engineering of the organ-source pig and (2) the administration of novel immunosuppressive agents. Pig kidney transplants have now supported immunosuppressed (anephric) nonhuman primates for periods in excess of a year, although this cannot be achieved consistently. The pig kidney graft can fulfill almost all of the functional requirements of a human kidney. The potential risks of infection with a pig microorganism will be minimized by the breeding and housing of the organ-source pigs in biosecure \"clean\" environments. For the first formal clinical trial, we suggest that diabetic patients on the waiting list aged 55-65 years with blood group O or B who are unlikely ever to receive a deceased human donor kidney might accept a pig kidney if it will negate the need for dialysis for 1 or more years.</p>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"7 8","pages":"101041"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309947/pdf/","citationCount":"0","resultStr":"{\"title\":\"Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig Kidney Xenotransplantation.\",\"authors\":\"Liaoran Wang, Maho Terashita, Kohei Kinoshita, Akihiro Maenaka, Ivy A Rosales, David K C Cooper\",\"doi\":\"10.1016/j.xkme.2025.101041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In patients with end-stage kidney disease, kidney transplantation from a living or deceased human donor offers a much-improved quality and length of life. Gene-edited pigs might provide an alternative source of kidneys for clinical transplantation (xenotransplantation). The major pathobiological barriers to successful pig kidney xenotransplantation have steadily been overcome by the following methods: (1) genetic engineering of the organ-source pig and (2) the administration of novel immunosuppressive agents. Pig kidney transplants have now supported immunosuppressed (anephric) nonhuman primates for periods in excess of a year, although this cannot be achieved consistently. The pig kidney graft can fulfill almost all of the functional requirements of a human kidney. The potential risks of infection with a pig microorganism will be minimized by the breeding and housing of the organ-source pigs in biosecure \\\"clean\\\" environments. For the first formal clinical trial, we suggest that diabetic patients on the waiting list aged 55-65 years with blood group O or B who are unlikely ever to receive a deceased human donor kidney might accept a pig kidney if it will negate the need for dialysis for 1 or more years.</p>\",\"PeriodicalId\":17885,\"journal\":{\"name\":\"Kidney Medicine\",\"volume\":\"7 8\",\"pages\":\"101041\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12309947/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.xkme.2025.101041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.xkme.2025.101041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Future Therapy for End-Stage Kidney Failure: Gene-Edited Pig Kidney Xenotransplantation.
In patients with end-stage kidney disease, kidney transplantation from a living or deceased human donor offers a much-improved quality and length of life. Gene-edited pigs might provide an alternative source of kidneys for clinical transplantation (xenotransplantation). The major pathobiological barriers to successful pig kidney xenotransplantation have steadily been overcome by the following methods: (1) genetic engineering of the organ-source pig and (2) the administration of novel immunosuppressive agents. Pig kidney transplants have now supported immunosuppressed (anephric) nonhuman primates for periods in excess of a year, although this cannot be achieved consistently. The pig kidney graft can fulfill almost all of the functional requirements of a human kidney. The potential risks of infection with a pig microorganism will be minimized by the breeding and housing of the organ-source pigs in biosecure "clean" environments. For the first formal clinical trial, we suggest that diabetic patients on the waiting list aged 55-65 years with blood group O or B who are unlikely ever to receive a deceased human donor kidney might accept a pig kidney if it will negate the need for dialysis for 1 or more years.